Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kalhs, Peter  [Clear All Filters]
2020
Strobl J, Pandey RVinay, Kausgruber T, Kleißl L, Reininger B, Herac M, Bayer N, Krall C, Wohlfarth P, Mitterbauer M, et al. Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease. J Invest Dermatol. 2020.
Rodríguez-Arbolí E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, Blau IWolfgang, Kröger N, Kalhs P, Forcade E, et al. FLAMSA-based reduced intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an ALWP/EBMT analysis. Biol Blood Marrow Transplant. 2020.
2014
Brüggen M-C, Petzelbauer P, Greinix H, Contassot E, Jankovic D, French L, Socié G, Rabitsch W, Kuzmina Z, Kalhs P, et al. Epidermal Elafin Expression is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. J Invest Dermatol. 2014.
Bojic M, Berghoff AS, Troch M, Agis H, Sperr WR, Widhalm G, Wöhrer A, Kalhs P, Preusser M, Rabitsch W. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: Single centre experience and literature review. Eur J Haematol. 2014.
2013
Brüggen M-C, Klein I, Greinix H, Bauer W, Kuzmina Z, Rabitsch W, Kalhs P, Petzelbauer P, Knobler R, Stingl G, et al. Diverse T cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood. 2013.